A Hydrazine–Hydrazone Adamantine Compound Shows Antimycobacterial Activity and Is a Probable Inhibitor of MmpL3
Tuberculosis remains an important cause of morbidity and mortality throughout the world. Notably, an important number of multi drug resistant cases is an increasing concern. This problem points to an urgent need for novel compounds with antimycobacterial properties and to improve existing therapies....
Main Authors: | Julien Briffotaux, Yanji Xu, Wei Huang, Zhen Hui, Xiao Wang, Brigitte Gicquel, Shengyuan Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/20/7130 |
Similar Items
-
The Mycobacterium tuberculosis MmpL3 inhibitor MSU-43085 is active in a mouse model of infection
by: John T. Williams, et al.
Published: (2024-01-01) -
Cryo-EM structure of the trehalose monomycolate transporter, MmpL3, reconstituted into peptidiscs
by: Julie Couston, et al.
Published: (2023-01-01) -
Repurposing Based Identification of Novel Inhibitors against MmpS5-MmpL5 Efflux Pump of <i>Mycobacterium smegmatis</i>: A Combined In Silico and In Vitro Study
by: Mohd Shahbaaz, et al.
Published: (2022-01-01) -
MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections
by: Jigar P. Sethiya, et al.
Published: (2020-08-01) -
MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature
by: Mohd. Imran, et al.
Published: (2022-11-01)